射频消融联合支气管动脉灌注化疗治疗中晚期非小细胞肺癌26例

Radiofrequency Ablation Combined with Bronchial Artery Infusion Chemotherapy in the Treatment for 26 Cases with Advanced NSCLC

[目的]评价射频消融联合吉西他滨、顺铂经支气管动脉灌注化疗治疗中晚期非小细胞肺癌的临床疗效。[方法]26例中晚期非小细胞肺癌患者,采用吉西他滨、顺铂经支气管动脉化疗灌注化疗,于首次化疗后3周左右在CT引导下对病灶进行射频消融治疗1次,随访并记录术后3个月、半年、1年的有效率、生存率与生活质量。并与单纯采用吉西他滨、顺铂经支气管动脉灌注化疗的27例对照组患者进行有效率与生存率的比较。[结果]联合组术后3个月、半年、1年有效率/生存率分别为92.3%/100%、76.9%/96.2%、46.2%/84.6%,对照组有效率/生存率分别为85.2%/100%、63.0%/85.2%、25.9%/66.7%,联合治疗组有效率与生存率均明显高于对照组(P<0.05)。联合组生活质量高于对照组(P<0.05)。[结论]射频消融联合吉西他滨、顺铂经支气管动脉灌注化疗治疗中晚期非小细胞肺癌具有较好的临床疗效,是一种较为理想、安全有效的综合性治疗手段。

[Purpose] To investigate the clinical efficacy of radiofrequency ablation （RFA） combined with in bronchial artery infusion （BAI） chemotherapy with gemcitabine and cisplatin for advanced non-small cell lung cancer （NSCLC）. [Methods] Twenty-six cases with advanced NSCLC underwent BAI chemotherapy with gemcitabine and cisplatin. Three weeks after the first BAI CT-guided RFA was performed. All patients were followed-up, response and survival rate at 3 months, 6 months and 1-year were recorded. The response and survival were compared with control group （27 patients underwent BAI chemotherapy with gemcitabine and cisplatin alone）. [Results] The 3 months, 6 months and 1-year response rate and survival rate in combination group （92.3%, 100%; 76.9%, 96.2%; 46.2%, 84.6%） were significantly higher than those in con- trol group （85.2%, 100%; 63.0%, 85.2%; 25.9%, 66.7%）（P〈0.05）. The quality of life in combination group was higher than that in control group （P〈0.05）. [Conclusion] RFA chemotherapy with gemcitabine and cisplatin combined with BAI is an effective, ideal and safe comprehensive treatment for advanced NSCLC.